2 Vaccinations provided no protection against Omicron infection 6 months later – New England J. of Medicine
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Heba N. Altarawneh, M.D., Hiam Chemaitelly, Ph.D., Houssein H. Ayoub, Ph.D., Patrick Tang, M.D., Ph.D., Mohammad R. Hasan, Ph.D., Hadi M. Yassine, Ph.D., Hebah A. Al-Khatib, Ph.D., Maria K. Smatti, M.Sc., Peter Coyle, M.D., Zaina Al-Kanaani, Ph.D., Einas Al-Kuwari, M.D., Andrew Jeremijenko, M.D., et al.
Some of the many charts: similar for both vaccines and both BA.1 and BA.2 at 6 months
BACKGROUND
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) variant is unclear.
METHODS
We conducted a national, matched, test-negative, case–control study in Qatar from December 23, 2021, through February 21, 2022 , to evaluate the effectiveness of vaccination with
BNT162b2 (Pfizer–BioNTech) or
mRNA-1273 (Moderna),
natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic omicron infection and against severe, critical, or fatal coronavirus disease 2019 (Covid-19).
RESULTS
The effectiveness of previous infection alone against symptomatic BA.2 infection was 46.1% (95% confidence interval [CI], 39.5 to 51.9). The effectiveness of vaccination with two doses of BNT162b2 and no previous infection was negligible (−1.1%; 95% CI, −7.1 to 4.6), but nearly all persons had received their second dose more than 6 months earlier. The effectiveness of three doses of BNT162b2 and no previous infection was 52.2% (95% CI, 48.1 to 55.9). The effectiveness of previous infection and two doses of BNT162b2 was 55.1% (95% CI, 50.9 to 58.9), and the effectiveness of previous infection and three doses of BNT162b2 was 77.3% (95% CI, 72.4 to 81.4). Previous infection alone, BNT162b2 vaccination alone, and hybrid immunity all showed strong effectiveness (>70%) against severe, critical, or fatal Covid-19 due to BA.2 infection. Similar results were observed in analyses of effectiveness against BA.1 infection and of vaccination with mRNA-1273.
CONCLUSIONS
No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. Vaccination enhanced protection among persons who had had a previous infection. Hybrid immunity resulting from previous infection and recent booster vaccination conferred the strongest protection. (Funded by Weill Cornell Medicine–Qatar and others.)
📄 Download the PDF from VitaminDWiki
Clipped from PDF
"Qatar has an unusually young, diverse population only 9% of its residents are 50 years of age or older..."
Study was reviewed at The Defender
Pfizer, Moderna COVID Vaccines May Increase Risk of Infection, Study Shows
VitaminDWiki – COVID-19 treated by Vitamin D - studies, reports, videos
{include}
At first symptoms that might be COVID, Vaccinated and Unvaccinated should take a Vitamin D loading dose
Take lots of Vitamin D at first signs of COVID 200,000 IU
"
VitaminDWiki pages with VACCIN in title (173 as of Aug 2022)
This list is automatically updated
{LIST()}